Hämorrhagische Diathesen
Author:
Meyer Oliver,Riess Hanno
Reference20 articles.
1. Andres O, König EM, Althaus K et al.; THROMKIDplus Study Group of the Society of Paediatric Oncology Haematology (Gesellschaft für Pädiatrische Onkologie und Hämatologie, GPOH) and the Society of Thrombosis Haemostasis Research (Gesellschaft für Thrombose- und Hämostaseforschung, GTH). Use of Targeted High-Throughput Sequencing for Genetic Classification of Patients with Bleeding Diathesis and Suspected Platelet Disorder. TH Open, 2018 Dec 30;2(4): e445–e454. 2. Arruda VR, Doshi BS, Samelson-Jones BJ. Emerging therapies for hemophilia: controversies and unanswered questions. F1000Res, 2018; 1–57. 3. Audia S, Mahevas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev, 2017; 16: 620–632. 4. Batty P, Lillicrap D. Hemophilia Gene Therapy: Approaching the First Licensed Product. Hemasphere, 2021 Feb 10;5(3): e540–e548. 5. Budde U, Schneppenheim R, Eikenboom J et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD) J Thromb Haemost, 2006; 6: 762–771.
|
|